Uterine fibroid

More than 1.5 Billion Women Worldwide Lack Essential Health Screenings

Retrieved on: 
Wednesday, September 21, 2022
Health, Medical Devices, Consumer, Infectious Diseases, Women, Health Technology, General Health, Adult, Gaps, Cervical cancer, COVID-19, Woman, Health minister, HOLX, Society, Dream, Population, Diabetes, Patient, Uterine fibroid, Degenerative disease, Opinion, Cancer, Breast cancer, CEO, Quality of life, Female, Gallup, Nasdaq, Healthcare disparity in Massachusetts, Leadership, Food, Ageing, Research, Anger, Health care, Awareness, Annual report, Hologic, Disease, Sadness, Risk management, Insurance, Birth control, Medicine, Medical imaging, Safety, Index, Health

More than 1.5 billion women worldwide lack screenings for cancer, heart disease, diabetes or sexually transmitted diseases/infections even though these conditions together affect billions of women.

Key Points: 
  • More than 1.5 billion women worldwide lack screenings for cancer, heart disease, diabetes or sexually transmitted diseases/infections even though these conditions together affect billions of women.
  • The barriers also fuel record-high levels of worry, stress, sadness and anger among women worldwide.
  • It looks at five interlocking dimensions of womens health: Preventive Care, Basic Needs, Opinions of Health and Safety, Individual Health and Emotional Health.
  • Essential screenings: 60% of female respondents (representing more than 1.5 billion women worldwide) said they werent tested in the last year for cancer, high blood pressure, diabetes or sexually transmitted diseases/infections.

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
Friday, September 16, 2022
RSU, Employment, Safety, Woman, Twitter, NYSE, FDA, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infertility, Medicines and Healthcare products Regulatory Agency, LinkedIn, Review, Uterine fibroid, Pregnancy, Pain, Female, MHRA, EC, New Drug Application, GLOBE, Endometriosis, RWS, Man, USPI, Pharmaceutical industry

The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.

Key Points: 
  • The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
  • The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 37,700 common shares ofMyovant.
  • The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.

Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed

Retrieved on: 
Friday, September 16, 2022
Injection, Safety, Awareness, African, Social media, Patient, American Urological Association, Prostate cancer, EC, New Drug Application, Testosterone, Disease, PCIA, Sex, Food, Organization, Pain, Science, Roivant Sciences, Man, Depression, Woman, NYSE, Risk, Prostate-specific antigen, FDA, Medicines and Healthcare products Regulatory Agency, National Prostate Health Month, Review, Uterine fibroid, Pregnancy, Female, MHRA, GLOBE, Endometriosis, RWS, Twitter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infertility, LinkedIn, Cancer, Caregiver, LHRH, Education, Recurrence, USPI, Medical imaging, Birth control

BASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE:MYOV) today announced an educational campaign to inspire prostate cancer patients to speak up and seek support through authentic conversations, along with the sponsorship of educational opportunities for patients, providers, and caregivers during Prostate Cancer Awareness Month.

Key Points: 
  • BASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences(NYSE:MYOV) today announced an educational campaign to inspire prostate cancer patients to speak up and seek support through authentic conversations, along with the sponsorship of educational opportunities for patients, providers, and caregivers during Prostate Cancer Awareness Month.
  • Studies have repeatedly shown that many patients lack the resources and willingness to speak openly about their condition, and Prostate Cancer Awareness month presents the opportunity to address these findings through increased awareness and education.
  • It will play host to the new video series Men With Prostate Cancer Find Support which illustrates how valuable peer to peer support can be.
  • The videos also link to resources that provide listings of third-party directories for prostate cancer support groups.

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

Retrieved on: 
Thursday, September 15, 2022
Urethra, Bone, DePuy, Industry, Phrase, Hematuria, Health Canada, Louisiana State University, Technology, BS, Medical Corps (United States Army), Indian Medical Association, NASDAQ, United Nations Convention on Contracts for the International Sale of Goods, BPH, Adoption, VP, Food, AG, National Medical Products Administration, Brainlab, Company, Growth, MBA, CE, Biology, FDA, Humanitarian Device Exemption, Uterine fibroid, Medtronic, American Medical Association, GLOBE, TSX, Biological engineering, Prostate, MRI, Rectum, Regulation of tobacco by the U.S. Food and Drug Administration, Risk, Hyperthermia, Prostate cancer, Covidien, Pharmaceutical industry, IMRIS, Profound Pharma, Boston Scientific

At the same time, we are excited that he is leaving our commercial organization in such good hands.

Key Points: 
  • At the same time, we are excited that he is leaving our commercial organization in such good hands.
  • Ms. Goodman brings over 17 years of medical device sales experience, most recently serving as Profounds VP, U.S.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.

The Black Women's Health Imperative Celebrates 39th Anniversary with Series of Community Events

Retrieved on: 
Wednesday, September 14, 2022
Linda, Health, Communication, Black women, Campaign, Woman, Awareness, Policy, Social justice, Tobacco industry, Celebrity Family Feud, COVID-19, Industry, Black Women's Health Imperative, Campaign for Tobacco-Free Kids, IG, Black Mama White Mama, Health equity, Uterine fibroid, NFL, Racism, Breast cancer, Wellness, CEO, Fair Work Act 2009, Make Votes Matter, House, ABC, Research, Conference, National Voter Registration Act of 1993, Education, Color, House of Hope, Tobacco, Mother, Television, Mobile phone, Medicine, D.C, Black

ATLANTA, Sept. 14, 2022 /PRNewswire/ -- Today, the Black Women's Health Imperative, founded by Byllye Avery in 1983 as the National Black Women's Health Project, announced a series of events to commemorate its 39th anniversary and renewits commitment to improving the health and wellness of Black communities nationwide.

Key Points: 
  • ATLANTA, Sept. 14, 2022 /PRNewswire/ -- Today, the Black Women's Health Imperative, founded by Byllye Avery in 1983 as the National Black Women's Health Project, announced a series of events to commemorate its 39th anniversary and renewits commitment to improving the health and wellness of Black communities nationwide.
  • "After two years of virtual anniversary programming, we're excited thatthis year'sgatherings will allow us to safely reconnect with communities and advocacy networks in person," said Michelle Webb, Chief Marketing and Communications Officerof the Black Women's Health Imperative.
  • About the Black Women's Health Imperative:
    The Black Women's Health Imperative is the first and only national non-profit organization created for and by Black women dedicated to improving the health and wellness of our nation's 21million Black women and girls -- physically, emotionally, and financially.
  • Our core mission is advancing health equity and social justice for Black women, across their lifespan, through policy, advocacy, education, research, and leadership development.

Virtuoso Surgical Announces First Public Offering of Common Stock to Advance its Revolutionary Robotic System for Endoscopic Surgery

Retrieved on: 
Tuesday, September 13, 2022
Surgery, Medical Devices, Health, Robotics, Technology, National, VISE, Surgery, Gynaecology, Endoscopy, FDA, Elective surgery, Entrepreneurship, Sale, Company, Bladder cancer, Review, Nose, Chief medical informatics officer, Uterine fibroid, U.S. Securities and Exchange Commission, III, Technology, National Science Foundation, Interim, Financial Industry Regulatory Authority, Virtuoso, Doctor of Philosophy, Johns Hopkins University, Surgeon, Cadaver, ENT, Neurology, Vanderbilt University, Ear, SEC, Thorax, Urology, BPH, FACS, Medical device, Dentistry, Engineering, MD

Virtuoso Surgical has developed a robotic surgery system that radically improves minimally invasive endoscopic surgery.

Key Points: 
  • Virtuoso Surgical has developed a robotic surgery system that radically improves minimally invasive endoscopic surgery.
  • Virtuoso Surgicals offering is made under SEC Regulation A, Tier 2, which means that any U.S. person can invest in the Company .
  • The offering is for the sale of common stock, and this is the first offering of the Company's common stock to the public.
  • S. Duke Herrell, III, MD, FACS , Co-Founder, Interim CEO and Chief Medical Officer of Virtuoso Surgical, added, "We are excited about the opportunity to sell our common stock to the public.

Valerie A. Flores, MD, FACOG Joins Southern California Fertility Care Pioneer, Reproductive Partners - San Diego

Retrieved on: 
Wednesday, September 7, 2022
Endocrine Society, Yale School of Medicine, Endometriosis, University, National Institute, Brown University, Research, SAN, Time, Scientist, Polycystic ovary syndrome, Physician, Department, Endocrine Reviews, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Textbook, NIH, Reproductive Sciences, Education, Faculty, Alpert Medical School, Diversity, Journal, Gynaecology, Reproduction, MD, National Institutes of Health Clinical Center, Health, FACOG, Partner, Equity, Embryology, Metabolism, Yale University, Uterine fibroid, Woman, Task force, Interest group, Family, Patient, Medicine, Medical device, Infertility, Obstetrics, Lancet

SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Reproductive Partners - San Diego, located in La Jolla, California, has announced the addition of Valerie A. Flores, MD, FACOG to its expanding medical team.

Key Points: 
  • SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Reproductive Partners - San Diego, located in La Jolla, California, has announced the addition of Valerie A. Flores, MD, FACOG to its expanding medical team.
  • During her fellowship, Dr. Flores was accepted into the Reproductive Scientist Development Program, a National Institute of Health (NIH)-funded, physician-scientist development program.
  • "To say we are excited to have Dr. Flores joining our team is an understatement," Reproductive Partners San Diego co-founder V. Gabriel Garzo, MD says.
  • For more information about Reproductive Partners - San Diego visit, https://www.fertilityclinicsandiego.com/

Profound Medical to Participate in September Investor Conferences

Retrieved on: 
Tuesday, September 6, 2022
Bone, Technology, Urethra, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, National Medical Products Administration, Food, Hyperthermia, Rectum, Health Canada, TSX, GLOBE, Humanitarian Device Exemption, Conference, Company, FDA, Hematuria, MRI, Uterine fibroid, Prostate cancer, International Medical Corps, CE, Pharmaceutical industry, Medical imaging

TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in September.

Key Points: 
  • TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in September.
  • Lake Streets 6th Annual BIG Conference: Profound is scheduled to participate in a series of one-on-one meetings on Wednesday, September 14, 2022.
  • A.G.P.s Virtual MedTech Conference: Profound is scheduled to participate in a series of one-on-one meetings on Wednesday, September 21, 2022.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound Medical Provides TULSA-PRO® Reimbursement Update

Retrieved on: 
Friday, September 2, 2022
Phrase, Bone, CEO, Technology, Centers for Medicare & Medicaid Services, Current, Urethra, Regulation of tobacco by the U.S. Food and Drug Administration, OPPS, NASDAQ, Calendar, National Medical Products Administration, Category 1, CMS, Risk, Food, Hyperthermia, Rectum, Current Procedural Terminology, Health Canada, TSX, Hospital, BPH, GLOBE, Humanitarian Device Exemption, Medicare, CPT, FDA, Company, Hematuria, MRI, Uterine fibroid, Prostate cancer, Medical Corps (United States Army), CE, Growth, Adoption, Patient, Medical imaging, Health insurance, Pharmaceutical industry, Profound Pharma

TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S. reimbursement update for Transurethral Ultrasound Ablation (TULSA), performed with its TULSA-PRO system.

Key Points: 
  • TORONTO, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (Profound or the Company), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S. reimbursement update for Transurethral Ultrasound Ablation (TULSA), performed with its TULSA-PRO system.
  • Profound anticipates that an updated application, which will include 2022 utilization data, will be submitted at the appropriate time in 2023.
  • In July 2022, CMS released its proposed OPPS reimbursement rule for calendar year 2023.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Myovant Sciences to Participate at Upcoming Investor Conferences

Retrieved on: 
Friday, September 2, 2022
Endometriosis, Roivant Sciences, Safety, Female, NYSE, Pain, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Man, New Drug Application, Chief business officer, Food, LinkedIn, Review, GLOBE, Citigroup, USPI, Conference, FDA, MHRA, Twitter, EC, Uterine fibroid, Investor, Infertility, Woman, RWS, Pregnancy, Medicines and Healthcare products Regulatory Agency, Pharmaceutical industry, Security (finance)

Management will participate in one-on-one investor meetings.

Key Points: 
  • Management will participate in one-on-one investor meetings.
  • Baird 2022 Global Healthcare Conference on Tuesday, September 13, 2022 at 12:15 p.m. Eastern Time, Mr. Marek and Mr. Mehra will participate in a fireside chat.
  • Management will also participate in one-on-one investor meetings on September 13.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.